Investigating new treatments for Alzheimer's disease targeting tau protein.
The Alzheimer's Disease Tau Platform Clinical Trial
This study is looking at new treatments that target a protein called tau, which is connected to Alzheimer's disease, to see how well they work and if they are safe for people with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10932876 on NIH RePORTER |
What this research studies
This research focuses on developing and testing new therapies aimed at tau protein, which is linked to the severity of Alzheimer's disease (AD). The trial will evaluate multiple tau-directed therapies, both alone and in combination with anti-amyloid treatments, to assess their safety and effectiveness. By utilizing advanced biomarkers and imaging techniques, the study aims to accelerate the clinical development of these therapies. Patients will be monitored for their response to treatment using various biological markers, providing insights into the effectiveness of the therapies being tested.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals in the early stages of Alzheimer's disease, particularly those with preclinical or prodromal symptoms.
Not a fit: Patients with advanced Alzheimer's disease or those without tau pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease, potentially improving patient outcomes and quality of life.
How similar studies have performed: Previous research has shown promise in targeting tau protein for Alzheimer's treatment, indicating that this approach could lead to significant advancements in therapy.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Boxer, Adam L. — University of California, San Francisco
- Study coordinator: Boxer, Adam L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.